.:: Aurgalys Team ::.
Philippe Berthon, PhD
Chief Executive Officer – Evry-Paris France
Philippe Berthon is Founder and Chief Executive Officer of Aurgalys, also board member Essonne Economy Agency. Previously, Dr Berthon was Chief Executive Officer of Vaxon-Biotech (2004-2008), a company developing cancer immunotherapeutic products at late clinical development stages. Philippe founded UroGene in 1998, was CEO then President & CSO. UroGene was dedicated to urological diseases including cancer and incontinence, raised a total of €25M venture capital money, and was traded off to Groupe Pierre Fabre early 2005. Prior to these appointments, Dr Berthon was co-founder and CEO of CeRePP at Hospital Saint Louis, Paris, from 1995-1999; senior post-doctoral fellow at the Cancer Research Unit, University of York, UK, for 3 years; and research fellow at Paris VI University for 5 years. Dr Berthon co-authored more than 50 peer-reviewed international publications, received his PhD in Reproduction Physiology at Paris VI University, and graduated from Challenge+ Business and Administration program, HEC School of Management, Jouy en Josas, France. Philippe Berthon is member of France Biotech, of Société Française des Analystes Financiers (SFAF) and Association des Analystes Conseil en Investissement Financier et Transmission d’Entreprises (ACIFTE).
Manuel Vega, PhD
Aurgalys Partner – Evry-Paris France
Dr Vega is partner of Aurgalys based at the Evry-Paris office. Manuel Vega joined Aurgalys in 2010 from L&M Crecer, a business & technology consulting firm between Argentina and France. Previously, Dr Vega was founder and Chief Executive Officer of Nautilus Biotech (US and France) from 1999 to 2007, for which he closed €40M+ corporate deals and raised about €30M€, mostly in private equity financing. For his previous appointments, Dr Vega was Director Development & Production at Genethon, France (1997-1999) , Managing Director of Microgen, Argentina (1993-1995), and from 1988 to 1993 held several senior academic positions in major institutes (INSERM, EMBO), in France and Germany . Dr Vega co-authored 25 peer-reviewed international publications, received his PhD in Biology at Universidad Nacional del Sur, Argentina.
Mickael Dubourd, PhD
Head of Equity Research and Investor Relations – Evry-Paris France
Dr Mickael Dubourd joined Aurgalys in February 2012 as a Life Sciences and Healthcare analyst, in charge of our Euronext customers. Since 2014, Dr Dubourd is Affiliated Professor to Grenoble Business School. Previously Mickael was a postdoctoral research associate at Keck School of Medecine, University of Southern California in Los Angeles, USA, from 2009 to 2011. Mickael received an Advanced Master in Biotechnology Management from Grenoble Graduate School of Business, France in 2012, and completed his PhD in Medical Sciences from University College Dublin, Ireland in 2009. Dr Dubourd also holds a Biological Engineering Degree from Compiègne Tech University, France (2006). Mickael Dubourd is a member of Société Française des Analystes Financiers (SFAF).
Christophe Dombu, PhD
Analyst – Evry-Paris France
Dr. Christophe Dombu joined Aurgalys in January 2014 as a Life Sciences and Healthcare analyst. Christophe holds an advanced Master degree in Pharma/ Biotech management from Grenoble Graduate School of Business. Prior to that Christophe completed a PhD in 2012, in Nanomedicine at University of Lille 2. As a researcher, Christophe participated in several nanomedicine projects with potential application in oncology, metabolic diseases and vaccines. The diabetes project was awarded an OSEO (now Bpifrance) prize for entrepreneurship.
Jamila El Bougrini, PhD
Analyst – Evry-Paris France
Dr. Jamila El Bougrini joined Aurgalys in May 2015 as a Financial analyst dedicated to Life Sciences and Healthcare companies. Jamila obtained her PhD in Cellular and Molecular Biology in 2009 from University Paris XI and worked during 4 years in French institutions such as « Fondation ARC pour la recherche sur le cancer » and « Vaincre la mucoviscidose » as a scientific officer. She had the opportunity to work within European networks, and to lead several projects and calls for oncology and cystic fibrosis programs. In 2015, she completed her scientific background by an MBA in International Management from University Paris Dauphine and IAE Paris-Sorbonne.